You just read:

Mallinckrodt Will Conduct Phase 4 Trial of H.P. Acthar® Gel (Repository Corticotropin Injection) for Symptomatic Sarcoidosis

News provided by

Mallinckrodt plc

Oct 09, 2017, 06:20 ET